Enter assignee name

CIPO Patents = 1

EPO Patents = 3

Trademarks = 1

Forward Citations = 7

Loading Chart...

6 inventors (with patents filed for the assignee):

Koji Tamada (8 out of 22 patents)

Tomoya Miyakawa (8 out of 15 patents)

Masaaki Oka (5 out of 15 patents)

4. Shoichi Hazama (5 out of 11 patents)

5. Keiko Udaka (5 out of 13 patents)

6. Shun Doi (3 out of 5 patents)

8 patents: Sort by Forward Citations

1. 11491204 - Composition comprising poly I:C and LAG-3-IGG fusion protein (2022-11-08),

2. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

3. 11291718 - Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2022-04-05),

4. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

5. 10842848 - Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein (2020-11-24),

6. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-03-17),

7. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2020-01-21),

8. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells (2020-01-07),

Cytlimic Inc. is a biotechnology company dedicated to developing innovative therapeutics for the treatment of cancer. Our focus is on harnessing the power of the immune system to target and destroy cancer cells. With cutting-edge technology and a team of experienced researchers, we are committed to advancing the field of immuno-oncology and improving outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

8 Patents

#1,908 in Tokyo

#4,920 in Japan

Tokyo, Japan

Cytlimic Inc.